查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984093

基因融合检测市场：按技术、检体类型、应用和最终用户划分－2026-2032年全球市场预测

Gene Fusion Testing Market by Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因融合检测市场价值将达到 3.2453 亿美元，到 2026 年将成长至 3.4739 亿美元，到 2032 年将达到 4.9739 亿美元，复合年增长率为 6.28%。

主要市场统计数据
基准年 2025 3.2453亿美元
预计年份：2026年 3.4739亿美元
预测年份 2032 4.9739亿美元
复合年增长率 (%) 6.28%

对基因融合检测在诊断生态系统中的临床路径、转化研究和相关人员决策中的重要性进行了简洁且具有策略意义的概述。

基因融合检测已成为现代分子诊断和转化研究的关键要素，改变了肿瘤学、血液学和罕见疾病治疗路径中的临床决策。检测设计和分析流程的进步已将检测方法从单基因和细胞遗传学方法转向整合分子谱分析，从而揭示可靶向的融合基因、抗药性机制和疾病亚型。随着标靶治疗在临床应用中的日益普及，准确识别基因融合对于患者筛选、治疗监测以及合格医疗试验的入组资格至关重要。

技术融合、监管澄清和临床证据如何加速基因融合检测在临床环境中的标准化和更广泛应用。

基因融合检测领域经历了变革性的转变，这主要得益于技术融合、监管成熟和不断涌现的临床证据。细胞遗传学检测和单分析物检测曾一度占据主导地位，而如今，结合正交确证检测和高解析度分析的多模态策略已成为主流。次世代定序加速了这一转变，不仅扩大了已知和新型融合基因的检测范围，还使检查室能够整合工作流程，并缩短结果交付时间。

评估 2025 年美国关税对基因融合检测价值链的供应链、筹资策略和业务永续营运弹性的影响。

美国将于2025年实施的关税政策，为基因融合检测全球供应链中的相关人员带来了新的挑战。随着成本结构的变化和供应风险评估的更新，采购团队表示，试剂采购、设备购买和耗材供应管道都受到了更严格的审查。实验室和製造商正在探索双通路采购策略和库存缓衝机制，以缓解短期供应波动，同时确保为患者提供持续的检测服务。

针对特定细分市场的诊断和商业性见解，重点关注整个测试过程中的技术差异、检体限制、临床应用和最终用户工作流程要求。

优先考虑基因融合检测领域的投资和研发，需要深入了解特定片段的趋势。在选择技术时，必须考虑每种方法的独特优势和局限性，例如萤光原位杂合反应（FISH）、免疫组织化学、次世代定序和RT-PCR。此外，次世代定序本身也分为标靶panel定序、转录组定序和全基因测序等多种方法，每种方法在范围、分析复杂性和基础设施需求方面都存在差异。每种技术方法都需要不同的检验方法、生物资讯学流程和终端使用者培训，以确保临床层级的解读和结果的可重复性。

影响各司法管辖区实施、伙伴关係模式和营运策略的区域比较趋势：北美和南美、欧洲、中东和非洲以及亚太地区。

区域趋势对基因融合检测领域中相关人员的应用路径、合作机会和营运重点有显着影响。在美洲，服务提供模式由广泛的诊断检查室网络以及与临床中心和药物研发项目的高水准合作所塑造。该地区倾向于优先采用先进的定序技术，并建立与药物研发时间表和法律规范相符的伴随诊断。医院、参考实验室和产业合作伙伴之间的联合联盟通常能够进行多中心检验研究，并加速临床应用。

竞争格局分析着重于平台差异化、共同创新和策略伙伴关係，以推动临床整合和市场渗透。

基因融合检测领域的竞争格局呈现出多元化的特点，既有成熟的诊断公司，也有专业的定序平台供应商，还有专注于检测化学和生物资讯学的新兴创新者。领先的诊断开发公司正致力于打造端到端的解决方案，这些方案融合了检验的检测方法、强大的资讯学功能、规范的文檔以及针对医院和参考检查室客户量身定制的服务模式。平台提供者则透过提高通量、提升读取准确性以及与实验室资讯管理系统无缝整合来不断提升自身竞争力，从而最大限度地减少工作流程中断。

采取切实可行的策略行动，加强组织韧性，加快临床部署，并透过与整个诊断和治疗生态系统的合作来提高价值创造。

产业领导者应优先考虑一系列切实可行的倡议，以增强整个基因融合检测生态系统的韧性，加速临床部署，并创造新的价值。首先，投资于模组化、检验的工作流程，使检查室能够分阶段引入基于定序的检测方法，这将降低准入门槛，同时保持分析的严谨性。这种方法有助于逐步升级，减轻训练负担，从而促进医院和独立检查室的更广泛应用。

透明、多方面的研究途径，结合相关人员访谈、技术文献和案例研究，提供可操作的见解和建议。

本研究的综合结果是基于一种多方面方法，旨在交叉检验技术、临床和商业性观点。主要资讯来源包括实验室管理人员、分子病理学家、检体采集管理人员和临床试验相关人员的结构化访谈，并辅以与检测方法开发人员和平台提供者的直接咨询。次要分析涵盖了同行评审文献、监管指导文件、技术白皮书和产品手册，以检验分析方法和监管方面的考虑。在适用情况下，来自检查室的匿名营运案例研究提供了有关工作流程实施和检验挑战的真实世界背景。

综合策略结论，旨在协调技术能力、营运韧性和合作伙伴关係关係，以最大限度地发挥基因融合检测的临床潜力。

基因融合检测技术的成熟反映了技术创新、临床需求以及诊断开发商、医疗系统和製药合作伙伴之间策略合作的整合。随着基于定序的方法日益普及和检体处理技术的改进，将可靠的融合检测整合到常规诊断中的机会比以往任何时候都更加清晰。然而，要实现这一潜力，需要对检验的工作流程、供应链韧性以及协作证据的生成进行规划性投资，以证明其在不同患者群体中的临床效用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：基因融合检测市场：依技术划分

  • 萤光原位杂合反应
  • 免疫组织化学
  • 次世代定序
    • 标靶次世代定序
    • 转录组序列
    • 全基因组定序
  • 逆转录聚合酵素链锁反应

第九章：依检体类型分類的基因融合检测市场

  • 血
    • 电浆
    • 血清
  • 组织
    • 福马林固定石蜡包埋
    • 新鲜冷冻组织

第十章 基因融合检测市场：依应用领域划分

  • 血液学
    • 白血病
    • 淋巴瘤
  • 肿瘤学
    • 乳癌
    • 结肠癌
    • 肺癌
    • 摄护腺癌
  • 罕见疾病
    • 发展障碍
    • 神经肌肉疾病

第十一章 基因融合检测市场：依最终用户划分

  • 诊断检测实验室
    • 医院检查室
    • 独立检测实验室
  • 医院
    • 住院设施
    • 门诊部
  • 製药公司
    • 生技公司
    • 大型製药企业
  • 研究机构
    • 学术研究机构
    • 私人研究机构

第十二章 基因融合检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 基因融合检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 基因融合检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国基因融合检测市场

第十六章：中国基因融合检测市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amoy Diagnostics Co., Ltd.
  • Arima Genomics, Inc.
  • Biocare Medical, LLC
  • Biocartis NV
  • Caris Life Sciences
  • Danaher Corporation
  • Empire Genomics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics, Inc.
  • OncoDNA SA
  • Paragon Genomics, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated.
  • SOPHiA GENETICS SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-2E76C3E47FBF

The Gene Fusion Testing Market was valued at USD 324.53 million in 2025 and is projected to grow to USD 347.39 million in 2026, with a CAGR of 6.28%, reaching USD 497.39 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 324.53 million
Estimated Year [2026] USD 347.39 million
Forecast Year [2032] USD 497.39 million
CAGR (%) 6.28%

Concise strategic framing of gene fusion testing relevance to clinical pathways, translational research, and stakeholder decision-making in diagnostic ecosystems

Gene fusion testing has emerged as a pivotal component of modern molecular diagnostics and translational research, reshaping clinical decision-making across oncology, hematology, and rare disease pathways. Advances in assay design and analytic pipelines have shifted testing from single-gene or cytogenetic approaches toward integrated molecular profiles that reveal actionable fusions, resistance mechanisms, and disease subtypes. As the clinical adoption of targeted therapies expands, precise identification of gene fusions has become essential for patient selection, therapeutic monitoring, and eligibility for precision medicine trials.

This summary synthesizes technological evolution, regulatory and trade influences, segment-level dynamics, regional adoption patterns, competitive movements, and recommendations for industry stakeholders. It draws on evidence of laboratory workflow optimization, the rising role of sequencing-based modalities, and the interplay between sample handling constraints and assay sensitivity. The goal is to provide decision-makers with a concentrated, strategically framed narrative that highlights where investment, partnership, and operational focus can materially improve clinical utility and commercial traction.

Throughout the document, emphasis is placed on how integrated testing strategies and cross-disciplinary collaboration between diagnostic laboratories, clinical centers, pharmaceutical developers, and research institutions are redefining pathways from discovery to clinical implementation. In doing so, readers will gain an actionable perspective on where scientific capability intersects with market and regulatory realities to create opportunities for innovation and competitive differentiation.

How technological convergence, regulatory clarity, and clinical evidence are accelerating standardization and broader clinical adoption of gene fusion testing

The landscape for gene fusion testing has undergone transformative shifts driven by technological convergence, regulatory maturation, and evolving clinical evidence. Historically dominated by cytogenetic and single-analyte assays, the field now favors multi-modal strategies that combine orthogonal confirmation with high-resolution profiling. Next-generation sequencing has catalyzed this transition, enabling broader detection of canonical and novel fusions while allowing laboratories to consolidate workflows and reduce time-to-result variability.

Concurrently, the clinical utility of fusion detection has expanded beyond initial diagnostic categorization to include therapy selection, minimal residual disease evaluation, and companion diagnostic development. This evolution is complemented by improvements in sample processing, such as enhanced nucleic acid extraction from formalin-fixed paraffin embedded tissue and optimized plasma protocols for circulating nucleic acids, which collectively increase assay yield and broaden patient eligibility for noninvasive testing.

Market access drivers, including more nuanced reimbursement frameworks and clearer regulatory pathways for laboratory-developed tests and in vitro diagnostics, have supported the adoption of advanced assays in hospital-based and independent laboratories alike. Partnerships between diagnostic developers and pharmaceutical companies have also intensified as drug development increasingly predicates enrollment on molecularly defined populations. Taken together, these shifts indicate a maturing ecosystem where technological capability, clinical need, and commercial incentives align to accelerate the standardization and scaling of gene fusion testing.

Assessment of the 2025 United States tariff impacts on supply chains, procurement strategies, and operational resilience within gene fusion testing value chains

The introduction of United States tariffs in 2025 has created a new layer of complexity for stakeholders operating in global supply chains for gene fusion testing. Procurement teams report increased scrutiny of reagent sourcing, instrument purchases, and consumable pipelines as cost profiles shift and supply risk assessments are updated. Laboratories and manufacturers are evaluating dual-sourcing strategies and inventory buffers to mitigate near-term procurement volatility while maintaining continuity of testing services for patients.

Beyond procurement, the tariff environment has prompted strategic re-evaluation of regional manufacturing footprints and distribution networks. Some companies have accelerated localization of critical component manufacturing or pursued partnerships with domestic suppliers to reduce exposure to cross-border duties. Regulatory teams are also anticipating potential product requalification needs associated with component substitutions, driving closer collaboration between quality assurance, regulatory affairs, and supply chain functions.

Clinicians and laboratory directors emphasize that maintaining assay performance and turnaround times remains paramount; therefore, operational adjustments prioritize validated alternatives and compatibility testing to avoid disruptions to clinical workflows. In parallel, commercial teams are recalibrating pricing and contracting models with health systems and reference laboratories to absorb or pass through cost impacts based on customer negotiations and competitive dynamics. Overall, the tariff-driven environment is forcing a more resilient and flexible industry posture, with an emphasis on supply chain transparency, localized capabilities, and cross-functional coordination to sustain uninterrupted patient care.

Segment-focused diagnostic and commercial insights highlighting technology distinctions, sample constraints, clinical applications, and end-user workflow requirements across the testing continuum

A granular appreciation of segment-specific dynamics is essential for targeting investment and development priorities within the gene fusion testing domain. When examining technology, assessments need to reflect the distinct advantages and constraints of Fluorescence In Situ Hybridization, Immunohistochemistry, Next Generation Sequencing, and RT-PCR, noting that Next Generation Sequencing itself comprises targeted panels, transcriptome sequencing, and whole genome sequencing approaches that vary in breadth, analytical complexity, and infrastructure requirements. Each technological path demands different validation approaches, bioinformatics pipelines, and end-user training to ensure clinical-grade interpretation and reproducibility.

Sample type considerations strongly influence operational design and test accessibility. Blood-based workflows require protocols for plasma and serum processing that preserve circulating nucleic acids, while tissue workflows must account for formalin-fixed paraffin embedded specimens and fresh frozen tissue, each presenting trade-offs in nucleic acid integrity, turnaround, and histopathology integration. Application-driven segmentation highlights that hematology, oncology, and rare disease use cases impose divergent clinical thresholds for sensitivity, specificity, and reporting granularity. Within hematology, testing for leukemia and lymphoma informs therapeutic stratification and minimal residual disease assessment, whereas oncology applications in breast, colorectal, lung, and prostate cancers prioritize the detection of actionable fusions and mechanisms of resistance. Rare disease applications, including developmental disorders and neuromuscular conditions, often require broader transcriptomic interrogation and specialized interpretation frameworks.

End-user differentiation further shapes commercial approaches and service design. Diagnostic laboratories, both hospital-based and independent, emphasize throughput optimization and assay standardization; hospitals, across inpatient facilities and outpatient clinics, value rapid turnaround and integration with electronic health records; pharmaceutical companies, spanning biotechnology firms and larger pharma organizations, seek companion diagnostic partnerships and rigorous analytical validation to support clinical trials; and research institutions, including academic centers and private research laboratories, drive early-stage discovery and method development that can translate into clinical pipelines. Understanding these interconnected segments enables more precise prioritization of product features, go-to-market channels, and collaborative models that align technical capability with end-user workflows and interpretive needs.

Comparative regional dynamics that shape adoption, partnership models, and operational strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific jurisdictions

Regional dynamics materially influence adoption pathways, partnership opportunities, and operational priorities for gene fusion testing stakeholders. In the Americas, service delivery models are shaped by an extensive network of diagnostic laboratories and a high degree of integration between clinical centers and pharmaceutical development programs. This region tends to prioritize rapid implementation of advanced sequencing modalities and the establishment of companion diagnostics that align with drug development timelines and regulatory frameworks. Collaborative consortia between hospitals, reference labs, and industry partners frequently enable multi-site validation studies and accelerated clinical adoption.

In Europe, Middle East & Africa, the landscape is heterogeneous, with pockets of highly centralized national reference laboratory systems coexisting alongside decentralized hospital networks. Regulatory harmonization efforts and cross-border clinical collaborations are driving wider adoption in select markets, while health system procurement models and reimbursement pathways vary significantly. Stakeholders in this region often focus on demonstrating cost-effectiveness, clinical utility, and interoperability with diverse health IT infrastructures to gain adoption across public and private providers.

Across Asia-Pacific, rapid infrastructure investment and strong government support for precision medicine initiatives have catalyzed growth in both academic research and commercial testing capacity. Laboratories in several markets are scaling sequencing-based services and developing localized manufacturing capabilities to reduce reliance on imports. Regional public health priorities and population-specific genomic characteristics also shape test selection and assay validation strategies, prompting tailored approaches that reflect local clinical needs and sample availability. These regional nuances necessitate differentiated engagement models and strategic investment plans to optimize market entry, partnerships, and service delivery.

Competitive landscape analysis emphasizing platform differentiation, collaborative innovation, and strategic partnerships that drive clinical integration and market traction

Competitive activity in the gene fusion testing arena is defined by a mix of established diagnostic companies, specialized sequencing platform providers, and emerging innovators focused on assay chemistry and bioinformatics. Leading diagnostic developers are investing in end-to-end solutions that combine validated assays with robust informatics, regulatory documentation, and service models tailored to hospital and reference laboratory customers. Platform providers continue to differentiate through throughput capabilities, read accuracy, and seamless integration with laboratory information management systems to minimize workflow interruption.

At the same time, innovative entrants are pushing the boundaries of sensitivity and breadth through transcriptome-level approaches and novel library preparation chemistries that enable detection of complex or rare fusion events. These advancements often emerge from academic collaborations and private research labs before being adopted in clinical settings, underscoring the importance of strategic partnerships between research institutions and commercial entities. Pharmaceutical companies remain key collaborators, commissioning analytical validation studies and co-developing companion diagnostics to support targeted therapy programs.

Mergers, strategic alliances, and distribution agreements are common mechanisms for scaling global presence and addressing supply chain vulnerabilities. Companies that successfully combine strong technical platforms, validated clinical utility, and flexible commercial models are better positioned to secure long-term relationships with health systems and trial sponsors. Ultimately, competitive advantage accrues to organizations that balance innovation with regulatory rigor, operational reliability, and clear evidence of clinical impact.

Practical strategic actions for organizations to enhance resilience, accelerate clinical adoption, and strengthen collaborative value creation across diagnostic and therapeutic ecosystems

Industry leaders should prioritize a series of actionable initiatives to strengthen resilience, accelerate clinical adoption, and unlock new value across the gene fusion testing ecosystem. First, investing in modular, validated workflows that allow laboratories to adopt sequencing-based assays incrementally can lower barriers to entry while preserving analytical rigor. This approach facilitates stepwise upgrades and reduces training friction, enabling broader uptake among hospital-based and independent laboratories.

Second, strengthening supply chain transparency and diversifying sourcing strategies will mitigate tariff and disruption risks. Establishing qualified secondary suppliers for critical reagents and exploring regional manufacturing partnerships can minimize lead-time variability and protect assay continuity. Parallel to procurement strategies, stakeholders should institute robust change-control protocols that preemptively qualify alternative components without compromising performance.

Third, companies should deepen collaborations with pharmaceutical developers and clinical networks to co-develop companion diagnostics and prospective validation studies that demonstrate clinical utility. Aligning assay design with therapeutic development pipelines can accelerate patient access to targeted therapies and enhance the commercial value proposition. Finally, investing in clinician-facing education and standardized reporting templates will improve test interpretation, increase clinician confidence, and facilitate smoother integration into treatment decision pathways. These combined actions will position organizations to respond nimbly to external shocks while capturing opportunities created by technological innovation and evolving clinical demand.

Transparent multi-method research approach combining stakeholder interviews, technical literature, and operational case studies to underpin actionable insights and recommendations

This research synthesis is grounded in a multi-method approach designed to triangulate technical, clinical, and commercial perspectives. Primary inputs include structured interviews with laboratory directors, molecular pathologists, procurement leads, and clinical trial stakeholders, complemented by direct consultation with assay developers and platform providers. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, technical whitepapers, and product manuals to validate analytical approaches and regulatory considerations. Where applicable, anonymized operational case studies from laboratories provided real-world context on workflow implementation and validation challenges.

Analytical rigor was maintained through methodical cross-validation of technology performance characteristics, sample handling protocols, and end-user requirements. The methodology prioritized peer-reviewed evidence and primary stakeholder testimony to ensure recommendations reflect both scientific validity and operational feasibility. Sensitivity to regional regulatory and reimbursement environments informed the regional insights, while supply chain assessments integrated procurement data and supplier interviews to evaluate vulnerability and mitigation options.

Limitations inherent to any synthesis are acknowledged, including variability in reporting standards across laboratories and differences in local regulatory interpretation. To address these constraints, the methodology emphasizes transparency in data sources, explicit documentation of assumptions, and the provision of methodological appendices that detail interview guides, inclusion criteria, and validation checkpoints. This approach enables stakeholders to adapt findings to their specific operational contexts with confidence in the underlying evidence base.

Integrated strategic conclusions on aligning technical capability, operational resilience, and collaborative partnerships to realize the full clinical potential of gene fusion testing

The maturation of gene fusion testing reflects a convergence of technological innovation, clinical necessity, and strategic alignment among diagnostic developers, health systems, and pharmaceutical partners. As sequencing-based approaches become more accessible and sample processing improves, the opportunity to embed robust fusion detection into routine diagnostics has never been clearer. However, realizing that potential requires deliberate investments in validated workflows, supply chain resilience, and collaborative evidence generation that demonstrates clinical utility across diverse patient populations.

Stakeholders that act now to align assay design with end-user workflows, diversify supply networks, and engage in strategic partnerships with therapy developers will be best positioned to capitalize on scientific advances while safeguarding operational continuity. The evolving regulatory and reimbursement landscape rewards clarity of evidence and cross-sector collaboration, making early engagement with clinical and regulatory stakeholders a competitive differentiator. In conclusion, the gene fusion testing ecosystem is poised for sustained clinical integration, and organizations that pursue coordinated technical, commercial, and operational strategies will lead the next phase of translation from discovery to improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Fusion Testing Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Immunohistochemistry
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Next Generation Sequencing
    • 8.3.2. Transcriptome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Reverse Transcription Polymerase Chain Reaction

9. Gene Fusion Testing Market, by Sample Type

  • 9.1. Blood
    • 9.1.1. Plasma
    • 9.1.2. Serum
  • 9.2. Tissue
    • 9.2.1. Formalin Fixed Paraffin Embedded
    • 9.2.2. Fresh Frozen Tissue

10. Gene Fusion Testing Market, by Application

  • 10.1. Hematology
    • 10.1.1. Leukemia
    • 10.1.2. Lymphoma
  • 10.2. Oncology
    • 10.2.1. Breast Cancer
    • 10.2.2. Colorectal Cancer
    • 10.2.3. Lung Cancer
    • 10.2.4. Prostate Cancer
  • 10.3. Rare Diseases
    • 10.3.1. Developmental Disorders
    • 10.3.2. Neuromuscular Disorders

11. Gene Fusion Testing Market, by End User

  • 11.1. Diagnostic Laboratories
    • 11.1.1. Hospital Based Laboratories
    • 11.1.2. Independent Laboratories
  • 11.2. Hospitals
    • 11.2.1. Inpatient Facilities
    • 11.2.2. Outpatient Clinics
  • 11.3. Pharmaceutical Companies
    • 11.3.1. Biotechnology Companies
    • 11.3.2. Pharma Giants
  • 11.4. Research Institutions
    • 11.4.1. Academic Centers
    • 11.4.2. Private Research Laboratories

12. Gene Fusion Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Gene Fusion Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Gene Fusion Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Gene Fusion Testing Market

16. China Gene Fusion Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amoy Diagnostics Co., Ltd.
  • 17.6. Arima Genomics, Inc.
  • 17.7. Biocare Medical, LLC
  • 17.8. Biocartis NV
  • 17.9. Caris Life Sciences
  • 17.10. Danaher Corporation
  • 17.11. Empire Genomics, Inc.
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. Guardant Health, Inc.
  • 17.14. Illumina, Inc.
  • 17.15. Integrated DNA Technologies, Inc.
  • 17.16. Myriad Genetics, Inc.
  • 17.17. Natera, Inc.
  • 17.18. NeoGenomics, Inc.
  • 17.19. OncoDNA SA
  • 17.20. Paragon Genomics, Inc.
  • 17.21. QIAGEN N.V.
  • 17.22. Quest Diagnostics Incorporated.
  • 17.23. SOPHiA GENETICS SA
  • 17.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENE FUSION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 261. GCC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GCC GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. GCC GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 264. GCC GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 266. GCC GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 267. GCC GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. GCC GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. GCC GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. GCC GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. GCC GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GCC GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 273. GCC GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 275. GCC GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 306. G7 GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. G7 GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. G7 GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 309. G7 GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. G7 GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 311. G7 GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 312. G7 GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. G7 GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. G7 GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. G7 GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 316. G7 GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. G7 GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 318. G7 GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 319. G7 GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 320. G7 GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 321. NATO GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. NATO GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. NATO GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 324. NATO GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. NATO GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 326. NATO GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2032 (USD MILLION)
  • TABLE 327. NATO GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. NATO GE